Roche: positive data for Kadcyla in breast cancer
A 'statistically and clinically significant' improvement in overall survival (OS), a secondary endpoint, was observed with the adjuvant (post-surgical) Kadcyla (trastuzumab emtansine) compared to Herceptin (trastuzumab). At 7 years, OS rates were 89.07% and 84.37% for Kadcyla and Herceptin, respectively.
In addition, Kadcyla reduced the risk of disease recurrence or death from any cause by 46% compared with Herceptin.
"We are delighted that Kadcyla can offer people with HER2-positive early breast cancer with a particularly poor prognosis a chance to live longer, disease-free lives," said Levi Garraway, M.D., Ph.D., Roche's Medical Director and Chief Medical Officer.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction